Telefon:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@antikoerper-online.de

FLJ11730 (N-Term) Antikörper

Reaktivität: Human IHC, WB Wirt: Kaninchen Polyclonal unconjugated
Produktnummer ABIN630964
  • Target
    FLJ11730
    Bindungsspezifität
    N-Term
    Reaktivität
    • 2
    • 1
    • 1
    • 1
    • 1
    Human
    Wirt
    • 2
    Kaninchen
    Klonalität
    • 2
    Polyklonal
    Konjugat
    • 2
    Unkonjugiert
    Applikation
    • 2
    • 2
    • 1
    Immunohistochemistry (IHC), Western Blotting (WB)
    Spezifität
    FLJ11730 antibody was raised against the N terminal Of Flj11730
    Aufreinigung
    Affinity purified
    Immunogen
    FLJ11730 antibody was raised using the N terminal Of Flj11730 corresponding to a region with amino acids HNKAAPPQIPDTRRELAELVKRKQELAETLANLERQIYAFEGSYLEDTQM
  • Applikationshinweise
    WB: 0.5 µg/mL, IHC: 4-8 µg/mL
    Optimal conditions should be determined by the investigator.
    Kommentare

    FLJ11730 Blocking Peptide, catalog no. 33R-3801, is also available for use as a blocking control in assays to test for specificity of this FLJ11730 antibody

    Beschränkungen
    Nur für Forschungszwecke einsetzbar
  • Format
    Lyophilized
    Rekonstitution
    Lyophilized powder. Add distilled water for a 1 mg/mL concentration of FLJ11730 antibody in PBS
    Konzentration
    Lot specific
    Buffer
    PBS
    Handhabung
    Avoid repeated freeze/thaw cycles.
    Dilute only prior to immediate use.
    Lagerung
    4 °C/-20 °C
    Informationen zur Lagerung
    Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
  • Target
    FLJ11730
    Hintergrund
    The screening of cDNA expression libraries from human tumors with serum antibody (SEREX) has proven to be a powerful method for identifying the repertoire of tumor antigens recognised by the immune system of cancer patients, referred to as the cancer immunome. In this regard, cancer/testis (CT) antigens are of particular interest because of their immunogenicity and restricted expression patterns. Synoivial sarcomas are striking with regard to CT antigen expression, however, highly expressed in sarcoma, CT antigens do not induce frequent humoral immune responses in sarcoma patients. Sera from two patients were used to immunoscreen cDNA libraries from two synovial sarcoma cell lines and normal testis, resulting in the identification of 113 distinct antigens. Sarcoma antigen NY-SAR-91 is one of them.
    Molekulargewicht
    23 kDa (MW of target protein)
Sie sind hier:
Kundenservice